Last update 20 Mar 2025

Navicixizumab

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
Anti-DLL4/VEGF bispecific antibody, Navicixizumab (USAN/INN)
+ [1]
Action
inhibitors
Mechanism
DLL4 inhibitors(Delta-like protein 4 inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11126--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Platinum-Resistant Fallopian Tube CarcinomaPhase 2-30 Nov 2022
Platinum-Resistant Ovarian CarcinomaPhase 2-30 Nov 2022
Primary peritoneal carcinomaPhase 2-30 Nov 2022
Advanced Malignant Solid NeoplasmPhase 2
United States
05 Aug 2022
Colorectal CancerPhase 2
United States
05 Aug 2022
Ovarian CancerPhase 2
United States
05 Aug 2022
Stomach CancerPhase 2
United States
05 Aug 2022
Triple Negative Breast CancerPhase 2
United States
05 Aug 2022
Fallopian Tube CarcinomaPhase 1
United States
30 Jan 2022
Metastatic Colorectal CarcinomaPreclinical
United States
01 Dec 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
15
(hhwtlwxotw) = egjlcybkmw jvaoqsojkb (icfaakgpfs )
Negative
24 Jan 2023
(hhwtlwxotw) = djvbwhfdgb jvaoqsojkb (icfaakgpfs )
Phase 1
44
(sfcplwveor) = jqqluvmufc wnzijwxywu (uzeqajpgjd )
Positive
21 Apr 2022
Phase 1
44
nrhskxnaet(gejeplnikj) = 40.9% hyewxbdcse (vqesscypib )
Positive
19 Apr 2022
Phase 1
66
(jhhgfpkyuo) = fheqawwruj rdcvgaiuxt (tdsxmxkhro )
Positive
01 Jun 2019
Phase 1
18
(ottyqvjluf) = iqvwiymclk gjoojrtiuz (bzcbyqfleq )
Positive
20 Oct 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free